You are on Trendlyne United States. Click here to go to India website or make United States as your default
  1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : MAJOR PHARMACEUTICALS
  4. ASSEMBLY BIOSCIENCES INC

Assembly Biosciences Inc XNAS: ASMB

Assembly Biosciences Inc Live Share Price Today, Share Analysis and Chart

Download real time

9.56 0.00 (0.00%)

New 52W Low today

15,484 XNAS Volume

XNAS 01 Apr, 2025 1:20 PM (EDT)

Watchlist

Portfolio

Share

Assembly Biosciences Inc Key Metrics

Default

Market Capitalization

Below industry Median
71.7

PE TTM

Negative PE TTM
-1.8

PEG TTM

Negative PEG TTM
-0.1

Price to Book

Below industry Median
2.7

Institutional holding current Qtr %

Below industry Median
15.3

Revenue Growth Qtr YoY %

Below industry Median
2.7

Operating Revenue growth TTM %

High in industry
298.2

Net Profit Qtr Growth YoY %

Below industry Median
5.7

Net Profit TTM Growth %

Below industry Median
34.4

Operating Profit Margin TTM %

Negative Operating Profit Margin TTM %
-159.3

Piotroski Score

Below industry Median
2

Rel Perf vs Sector quarter%

-43.8
All financials are in USD Million and price data in USD
VIEW MORE

5

S

12

W

1

O

2

T

SWOT Analysis

Check P/E Buy Sell Zone

This stock has negative PE


Assembly Biosciences Inc Live Price Chart

Switch to TradingView
Created with Highcharts 9.0.1Chart context menu29. Apr27. May24. Jun22. Jul19. Aug16. Sep14. Oct11. Nov9. Dec6. Jan3. Feb3. Mar31. Mar20122014201620182020202220241020515250200kZoom1D1W1M3M1Y5YAllApr 1, 2024→Apr 1, 2025trendlyne.com

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Created with Highcharts 7.2.2Dec '22Dec '23Dec '24Dec '25Dec '2602040Actual RevenueAvg. Estimate
Hit

Assembly Biosciences Inc's Revenue was higher than average estimate 1 time in past 1 year

EPS forecast

Current EPS
-6.7
Avg. Estimate
-5.7
Low Estimate
-6.3
High Estimate
-5.1
Current EPS
Avg. Estimate
Hit

EPS is expected to grow by 15.1% in FY25

Consensus Recommendation

4 ANALYST Recommendations
BUY

Created with Highcharts 7.2.21Hold3Strong Buy

The consensus recommendation from 4 analysts for Assembly Biosciences Inc is BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get

Assembly Biosciences Inc Stock Analysis

Assembly Biosciences Inc stock analysis with key metrics, changes, and trends.

Assembly Biosciences Inc MetricVALUECHANGE %TRENDANALYSIS
Annual Revenue$28.52 M298.16%positive

Annual Revenue rose 298.16%, in the last year to $28.52 M. Its sector's average revenue growth for the last fiscal year was 7.47%.

Annual Net Profit$40.18 M34.38%positive

Annual Net Profit rose 34.38% in the last year to $40.18 M. Its sector's average net profit growth for the last fiscal year was -32.43%.

Price to Earning Ratio-1.79-negative

Price to Earning Ratio is -1.79, which is negative.

Stock Price$9.56-28.12%negative

Stock Price fell 28.12% and underperformed its sector by 32.29% in the past year.

Quarterly Revenue$7.36 M2.71%positive

Quarterly Revenue rose 2.71% YoY to $7.36 M. Its sector's average revenue growth YoY for the quarter was 5.97%.

Quarterly Net profit$10.34 M5.72%positive

Quarterly Net profit rose 5.72% YoY to $10.34 M. Its sector's average net profit growth YoY for the quarter was -47.4%.

Mutual Fund Holding8.43 %-0.87%negative

Mutual Fund Holding decreased by 0.87% in the last quarter to 8.43.

Promoter Share Holding0.28 %0%neutral

Promoter Share Holding stayed the same in the most recent quarter at 0.28%.

Institutional Holding15.26 %-0.89%negative

Institutional Holding decreased by 0.89% in the last quarter to 15.26.

VIEW LESS


Loading data..

Assembly Biosciences Inc - Company Profile

What does Assembly Biosciences Inc do?

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

Assembly Biosciences Inc Management structure

All Gross Remunerations are in USD
Mr. Jason A. Okazaki
Director, President, Chief Executive Officer and Principal Financial Officer
1.37 M
2023
Gross Remuneration
Year
Mr. William E. Delaney, PhD
Chief Scientific Officer
811.82 K
2023
Gross Remuneration
Year

Assembly Biosciences Inc FAQ

How is Assembly Biosciences Inc today?
Assembly Biosciences Inc today is trading in the red, and is down by 0.00% at 9.56.
Assembly Biosciences Inc is currently trading down 0.00% on an intraday basis. In the past week the stock fell -14.03%. stock has been down -39.42% in the past quarter and fell -28.12% in the past year. You can view this in the overview section.